Parker Bioscience’s UK site to see multi-million dollar investment through 2018

By Melissa Fassbender

- Last updated on GMT

Getty/Norasit Kaewsai
Getty/Norasit Kaewsai
Parker Bioscience’s UK-based site will be expanded as part of a multi-million dollar phased investment program to be completed throughout 2018.

Parker Hannifin has announced a major investment in its Parker Bioscience division, which supplies and delivers systems for upstream and downstream pharmaceutical and biopharmaceutical manufacturing. The division has sites in Birtley, UK and Oxnard, CA in the US.

The investment will expand Parker Bioscience’s laboratory, clean room, office and warehouse facilities. According to the company, it also will make the division’s Birtley premises “one of the most modern manufacturing sites for integrated bioprocessing solutions in EMEA.”

Mike Brailsford, General Manager at Parker Bioscience, said: “The increased capacity will help us to offer larger scale services to biopharmaceutical manufacturers in Europe and across the globe, and is a major milestone in the division’s growth.”

Parker Bioscience has not responded to a request for comment.

Related news

Related products

show more

High-Density Vero Cell Perfusion Culture

High-Density Vero Cell Perfusion Culture

Eppendorf for Bioprocess – Solutions that grow with you | 01-May-2018 | Application Note

Viral diseases like rabies, rotavirus and influenza are causing many deaths worldwide, resulting in a strong demand for more productive manufacturing techniques...

Featured eBook: Complex Protein Production

Featured eBook: Complex Protein Production

Catalent Pharma Solutions | 06-Mar-2018 | Technical / White Paper

Download the eBook written by Catalent experts to learn about innovative products and techniques for scale-up of complex biologics, get optimal cell culture...

Related suppliers

Follow us


View more